You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 9,138,404


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,138,404
Title:Treating critically ill patients with intravenous ibuprofen
Abstract: Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.
Inventor(s): Pavliv; Leo (Cary, NC), Rock; Amy Dix (Nashville, TN)
Assignee: Cumberland Pharmaceuticals Inc. (Nashville, TN)
Application Number:14/507,331
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 9,138,404: A Detailed Analysis

Introduction

Patent 9,138,404, like any other patent, is a complex document that outlines the exclusive rights granted to an inventor for their innovation. To fully comprehend the scope and claims of this patent, it is essential to delve into its specifics, the broader patent landscape, and the guidelines set by the United States Patent and Trademark Office (USPTO).

What is Patent 9,138,404?

To begin, one must identify the subject matter of the patent. However, without specific details from the patent itself, we can only generalize based on common practices and recent updates in patent law.

Patent Claims: An Overview

Patent claims are the heart of any patent, defining the scope of the invention and the rights granted to the patent holder. These claims must be clear, concise, and supported by the patent's description and drawings[4].

Types of Claims

There are generally two types of claims: independent and dependent claims.

  • Independent Claims: These stand alone and define the invention without reference to other claims.
  • Dependent Claims: These refer back to and further limit an independent claim, often adding additional features or details.

Subject Matter Eligibility

The USPTO's recent guidance updates, particularly those related to artificial intelligence (AI) and software technologies, are crucial for understanding the eligibility of patent claims. The 2024 USPTO guidance emphasizes the importance of integrating judicial exceptions into practical applications to ensure patent eligibility under 35 U.S.C. § 101[1].

Evaluating Practical Applications

The guidance highlights that claims must demonstrate a concrete technological improvement. For instance, if a claim involves an abstract idea, it must be transformed into a practical application through additional elements that impose meaningful limits on the exception. This is illustrated in examples provided by the USPTO, such as Example 48, where the use of separated audio components in a real-time speech recognition system enhances the accuracy of voice commands, thereby meeting the criteria for patent eligibility[1].

The Role of AI in Patent Eligibility

The 2024 USPTO guidance clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies. This means that AI’s role as a tool does not exclude inventions from eligibility, provided there is significant human contribution[1].

Recent Case Law and Examples

The USPTO's guidance incorporates recent Federal Circuit decisions, providing up-to-date legal standards and interpretations. New examples, such as Examples 47-49, are specifically tailored to AI technologies, illustrating how claims involving AI can meet the eligibility criteria. For example, Example 47 focuses on an artificial neural network designed to identify anomalies, showing how specific applications of neural networks can meet eligibility criteria by demonstrating an improvement in computer technology[1].

Searching and Analyzing Patents

To analyze the scope and claims of a specific patent like 9,138,404, one would typically use the USPTO's search tools. The Patent Public Search tool, for instance, provides enhanced access to prior art and allows for detailed searches of patent claims and descriptions[4].

Using Patent Databases

The USPTO offers various datasets and tools, such as the Patent Claims Research Dataset, which contains detailed information on claims from US patents and applications. This dataset can help in understanding the structure and scope of patent claims over time[3].

Patent Landscape and Trends

Understanding the broader patent landscape is crucial for contextualizing the scope and claims of a specific patent. This includes looking at trends in patent filings, the types of technologies being patented, and the legal and policy changes affecting patent law.

Impact of Recent Guidance

The 2024 USPTO guidance on AI and software technologies has significant implications for innovators and patent practitioners. It provides clearer guidelines on how to draft claims that are more likely to avoid section 101 rejections, which are common in software-related patent applications[1].

Practical Applications and Real-World Benefits

For a patent to be eligible, it must demonstrate real-world applications and tangible benefits. This is a key takeaway from the USPTO's examples and recent case law. Claims that merely involve abstract ideas or routine data processing without practical application are unlikely to be patent-eligible[1].

Conclusion

Analyzing the scope and claims of a patent like 9,138,404 requires a deep understanding of patent law, recent guidance updates, and the broader patent landscape. By focusing on practical applications, integrating judicial exceptions, and ensuring significant human contribution, inventors and patent practitioners can navigate the complex world of patent eligibility.

Key Takeaways

  • Practical Applications: Claims must demonstrate concrete technological improvements and real-world applications.
  • AI-Assisted Inventions: The use of AI in invention development does not impact subject matter eligibility.
  • Recent Case Law: The USPTO's guidance incorporates recent Federal Circuit decisions to ensure consistency and clarity.
  • Patent Search Tools: Utilize USPTO's search tools and datasets to analyze patent claims and descriptions.
  • Trends and Landscape: Understand the broader patent landscape and trends in patent filings.

FAQs

What is the significance of the 2024 USPTO guidance update on AI patents?

The 2024 USPTO guidance update refines and clarifies the process for determining the patent eligibility of AI-related inventions, providing examples and detailed eligibility analysis to help practitioners evaluate and draft patent-eligible claims[1].

How do AI-assisted inventions impact patent eligibility?

AI-assisted inventions are evaluated on equal footing with other technologies, with the focus remaining on the claimed invention itself. The use of AI does not exclude inventions from eligibility, provided there is significant human contribution[1].

What are the key elements for ensuring patent eligibility under the new guidance?

Claims must integrate judicial exceptions into practical applications, demonstrating concrete technological improvements and real-world benefits. Additional elements must impose meaningful limits on the exception to transform the claim into patent-eligible subject matter[1].

How can one search and analyze patent claims effectively?

Using the USPTO's Patent Public Search tool and other resources like the Patent Claims Research Dataset can help in detailed searches and analysis of patent claims and descriptions[3][4].

What is the role of recent case law in the USPTO's guidance?

Recent Federal Circuit decisions are integrated into the guidance to provide up-to-date legal standards and interpretations, promoting consistency and clarity in the application of patent eligibility criteria[1].

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. U.S. Patent and Trademark Office (USPTO) | USAGov
  3. Patent Claims Research Dataset - USPTO
  4. Search for patents - USPTO

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,138,404

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cumberland Pharms CALDOLOR ibuprofen SOLUTION;INTRAVENOUS 022348-002 Jun 11, 2009 RX Yes Yes ⤷  Subscribe ⤷  Subscribe METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.